Sumitomo Mitsui Trust Group’s BridgeBio Pharma BBIO Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$228K	Sell	3,067 -13	-0.4%	-$911	﹤0.01%	1057
2026 Q1	$229K	Buy	+3,080	New	+$223K	﹤0.01%	1029
2021 Q4	–	Sell	-6,508	Closed	-$305K	–	1170
2021 Q3	$305K	Sell	6,508 -181	-3%	-$9.7K	﹤0.01%	1144
2021 Q2	$408K	Sell	6,689 -281	-4%	-$16K	﹤0.01%	1123
2021 Q1	$429K	Sell	6,970 -658	-9%	-$43K	﹤0.01%	1091
2020 Q4	$542K	Buy	+7,628	New	+$368K	﹤0.01%	1061

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Sumitomo Mitsui Trust Group's BBIO Position: Q2 2026 in Review

Sumitomo Mitsui Trust Group reduced its BridgeBio Pharma (BBIO) stake by 0.42% in Q2 2026, selling an estimated $911 and leaving 3,067 shares worth $228K. The position accounts for ﹤0.01% of the portfolio, ranked #1057.

Sumitomo Mitsui Trust Group first reported a position in BBIO in Q4 2020 and has held it in 6 quarters since. The position peaked at $542K in Q4 2020. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Sumitomo Mitsui Trust Group held 3,067 shares of BridgeBio Pharma worth $228K as of Q2 2026.
Sumitomo Mitsui Trust Group sold 13 BridgeBio Pharma shares in Q2 2026, an estimated $911.
BridgeBio Pharma made up ﹤0.01% of Sumitomo Mitsui Trust Group's portfolio in Q2 2026, its #1057 holding.
Sumitomo Mitsui Trust Group first reported a position in BridgeBio Pharma in Q4 2020 and has held it in 6 quarters since.
Sumitomo Mitsui Trust Group's BridgeBio Pharma position peaked at $542K in Q4 2020.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q2 2026, filed 30 Jul 2026.